(Q34303895)

English

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

based on heuristic

inferred from title

allergic asthma

1 reference

based on heuristic

inferred from title

Anna Maria Riccio

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Giorgio Walter Canonica

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

R W Dal Negro

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Micheletto

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L De Ferrari

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Folli

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Chiappori

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

International Journal of Immunopathology and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

475-484

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Asthma: clinical expression and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Italian real-life experience of omalizumab.

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Therapeutic targets for persistent airway inflammation in refractory asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Muscle and Mucous Gland Size in the Major Bronchi of Patients with Chronic Bronchitis, Asthma, and Asthmatic Bronchitis1–3

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Clinical relevance of airway remodelling in airway diseases

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma.

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Asthma: defining of the persistent adult phenotypes

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Asthma: a disease remodeling the airways

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Persisting Remodeling and Less Airway Wall Eosinophil Activation in Complete Remission of Asthma

1 reference

https://api.crossref.org/works/10.1177%2F039463201202500217

21 January 2018

Identifiers

10.1177/039463201202500217

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22697079%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34303895&oldid=1950513194"